BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28

• 

  Drug Development

  Novo Nordisk’s Positive Phase III Data for Oral Diabetic Drug Heats Up the Competition

  In an already competitive diabetes market, Novo Nordisk may have gained a significant edge with the results of its Phase III trial of GLP-1 drug oral semaglutide.

  February 22, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Pharm Country

  Reported Side Effects Raise Concerns for Regeneron’s Eylea

  Shares of Regeneron are down following reports of increased observations of known side effects from blockbuster drug Eylea were reported by providing doctors.

  February 22, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Gilead’s Kite Teams Up with Sangamo Therapeutics for Cancer Therapeutics in a $3.1 Billion+ Deal

  Kite, a Gilead Company, has inked a worldwide collaboration deal with Sangamo Therapeutics to develop oncology therapeutics.

  February 22, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  FDA

  Novartis Eyes 2019 for Launch of Investigational nAMD treatment

  Novartis is eying a possible 2019 launch for RTH258 (brolucizumab), an ophthalmology drug for the treatment of neovascular age-related macular degeneration.

  February 22, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Achillion Slashes Staff and Initiates Restructuring Following Termination of J&J Deal

  Achillion is handing out pink slips to 20 percent of its employees and initiating an operational restructuring plan.

  February 22, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Pharm Country

  Kallyope Snags $66M in Series B to Continue Gut-Brain Axis Research

  New York-based Kallyope Inc. has secured an additional $66 million in Series B funding that it will use to continue its work harnessing the communicative pathways between the digestive tract and the brain to develop new therapies for various illnesses.

  February 22, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Cannabis Company GW Pharmaceuticals’ Seizure Drug Flunks Phase II Trial

  GW Pharmaceuticals announced that its pipeline compound GWP42006 failed to meet its primary endpoint in a Phase IIa proof of concept study for patients with focal seizures.

  February 22, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Vertex Pharmaceuticals Launches Triple Combo Cystic Fibrosis Clinical Trial Earlier than Expected

  Vertex Pharmaceuticals announced it is starting its first Phase III trial of VX-659, a triple combination of the VX-659, tezacaftor and ivacaftor for cystic fibrosis.

  February 22, 2018

   · 

  2 min read

   · 

  Mark Terry
• Pharm Country

  The Chuck Noll Foundation For Brain Injury Research Announces Inaugural Research Grants

  Pittsburgh region scores high in traumatic brain injury research

  February 22, 2018

   · 

  5 min read
• Business

  Benitec Biopharma reports financial results for the 2018 fiscal second quarter and provides operational update

  Benitec Biopharma Ltd today reported its consolidated financial results for the 2018 fiscal second quarter to 31 December 2017 (2Q FY18), and highlighted recent progress in advancing its pipeline.

  February 22, 2018

   · 

  7 min read